etrasimod — Medica

Initial criteria

• Patient has moderately to severely active ulcerative colitis
• age ≥ 18 years
• Medication is prescribed by or in consultation with a gastroenterologist

Reauthorization criteria

• Patient has been established on therapy for at least 6 months
• Patient experienced a beneficial clinical response from baseline as assessed by at least one objective measure (e.g., fecal calprotectin, C-reactive protein, endoscopic assessment, or reduced corticosteroid dose) OR patient experienced an improvement in at least one symptom such as decreased pain, fatigue, stool frequency, or rectal bleeding

Approval duration

initial: 6 months; reauth: 1 year